References
- NeogiTClinical practice. GoutN Engl J Med20113645 443 45221288096
- TerkeltaubREdwardsNLGout: Diagnosis and Management of Gouty Arthritis and Hyperuricemia3rd edWest Islip, NYProfessional Communications, Inc2013
- KhannaDFitzgeraldJDKhannaPP2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care Res (Hoboken)20126410 1431 144623024028
- RichettePDohertyMPascualE2016 updated EULAR evidence-based recommendations for the management of goutAnn Rheum Dis2017761 29 4227457514
- DohertyMJansenTLNukiGGout: why is this curable disease so seldom cured?Ann Rheum Dis20127111 1765 177022863577
- BeckerMAFitz-PatrickDChoiHKAn open-label, 6-month study of allopurinol safety in gout: The LASSO studySemin Arthritis Rheum2015452 174 18326190562
- SinghJAAkhrasKSShiozawaAComparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohortArthritis Res Ther201517 12025963969
- Zurampic (lesinurad)AstraZeneca Available from: http://www.azpicentral.com/zurampic/zurampic.pdf#page=1Accessed January 6, 2017
- ReginatoAMMountDBYangIChoiHKThe genetics of hyperuricaemia and goutNat Rev Rheumatol2012810 610 62122945592
- SoAThorensBUric acid transport and diseaseJ Clin Invest20101206 1791 179920516647
- GirardetJ-LMinerJNUrate crystal deposition disease and gout-new therapies for an old problemAnnu Rep Med Chem201449 151 164
- U.S. Department of Heath and Human Services Food and Drug AdministrationGuidance for Industry. Bioanalytical Method ValidationU.S. Department of Heath and Human Services Food and Drug Administration Available from: http://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdfAccessed January 16, 2017
- ShenZRowlingsCKerrBPharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult malesDrug Des Devel Ther20159 3423 3434